Related Experiment Video
Updated: Sep 19, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose
A Zapatero1, M Roch2, C Martín de Vidales3
1Radiation Oncology Department, Hospital Universitario de La Princesa, Health Research Institute IIS-IP, Diego de León 62, 28006, Madrid, Spain. almudena.zapatero@salud.madrid.org.
Background/Purpose:
Dose escalation has demonstrated a significant improvement in biochemical recurrence in high-risk prostate cancer (HRPCa). We evaluated the impact on overall survival (OS) of dose intensification with external beam radiation therapy (EBRT) in a cohort of HRPCa patients treated in a single institution.
Methods And Materials:
Between January 1997 and January 2024, a total of 1451 consecutive localized PCa patients were treated with primary EBRT alone as part of a prospective institutional program for risk-adapted dose-intensification radiotherapy. For the present analysis, we specifically selected a cohort of 424 consecutive HRPCa patients with a minimum follow-up (FU) of 5 years. The median RT dose was 79.2 Gy (interquartile range [IQR] 74.9-80.3). Short and long-term hormones were administered in 56 (13%) and 350 (83%) of patients respectively. Kaplan-Meier curves were used to calculate overall survival (OS). Cumulative incidence of distant metastasis (DM), and cause specific survival (CSS) were estimated using competing risk regression.
Results:
Median patient age was 69 years (IQR 65-72) and median FU was 118 months (IQR 88.0-135.0). At the time of analysis, 54 of 424 patients (13%) had died. The leading cause of death was cardiovascular disease in 16/54 patients (4%), followed by PCa in 15 patients (3%). At 10 and 15 years, the KM estimated OS rates were 91% (95% CI 87-93) and 71% (95% CI 61-79), respectively. The corresponding rates for MFS were 87% (95% CI 83-90) and 60% (95% CI 49-68), and for CSS were 97% (95% CI 95-99) and 90% (95% CI 49-81), respectively. In multivariate analysis, when adjusted for patient age, T stage, Gleason/ISUP group, PSA and length of hormone-therapy, higher radiation dose remained significantly associated with an improved OS (HR 0.89; 95% CI 0.84-0.94), MFS (HR 0.94; 95% CI 0.90-0.98) and CSS (HR 0.89; 95% CI 0.84-0.94).
Conclusions:
The present study confirms that radiation dose intensification is paramount in the treatment of HRPCa with independence of duration of ADT.
More Related Videos
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Related Concept Videos
02:59Biological Effects of Radiation
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:17Radiation: Applications
The average...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...